Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: A randomised, two-way crossover, controlled clinical trial

Journal of Asthma

Volumn 50, Issue 10, 2013, Pages 1077-1082

  Bareille, Philippe ^a   Hardes, Kelly ^a   Donald, Alison C ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Corticosteroid steroid; Diskhaler; FEV1; Glucocorticoid; Inhaled

Indexed keywords

FLUTICASONE PROPIONATE; GW 870086; PLACEBO;

ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PERIPHERAL VASCULAR DISEASE; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; ASTHMA; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; STEROIDS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84887805216     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.837480     Document Type: Article

References (17)

1. Barnes PJ. Corticosteroid effects on cell signalling. Eur Resp J 2006;27:413-426.
2. Newton R, Holden NS. Separating transrepression and transactivation: A distressing divorce for the glucocorticoid receptor? Mo Pharmacol 2007;72:799-809.
3. Uings I, Needham D, Matthews J, Haase M, Austin R, Biggadike K, Farrow S. GW870086: A potent anti-inflammatory steroid with a unique pharmacological profile. Br J Pharmacol 2013;169: 1389-1403.
4. Allen A, Bareille P, Hardes K, Robertson J. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of GW870086. Current Drug Therapy 2013;8:76-85.
5. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2011. Available from: Http:// www.ginasthma.org/ [last accessed 28 Nov 2012].
6. British Thoracic Society & Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: A national clinical guideline. SIGN guideline 101. Edinburgh: SIGN, 2012.
7. National Heart, Blood and Lung Institute (NHBLI). Guidelines for the diagnosis and management of asthma. 2007. Available from: Http://www.nhlbi.nih. gov/guidelines/asthma/index.htm [last accessed 8 Nov 2012].
8. Berger WE, Ford LB, Mahr R, Nathan RA, Crim C, Edwards L, Wightman DS, et al. Efficacy and safety of fluticasone propionate 250 ug administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids. Ann Allergy Asthma Immunol 2002;89:393-399.
9. Bareille P, Allen A, Hardes K, Robertson J. Effect of repeat doses of GW870086 on the allergen-induced early and late asthmatic response in subjects with mild asthma. Current Drug Therapy (in press)
10. Zeiger RS, Baker JW, Kaplan MS, Pearlman DS, Schatz M, Bird S, Hustad C, Edelman J, for the mIAMI Study Research Group. Variability of symptoms in mild persistent asthma: Baseline data from the MIAMI study. Respir Med 2004;98:898-905.
11. Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials: For JACI Theme Issue on 'The Role of the Allergist-Immunologist in Personalized Medicine'. J Allergy Clin Immunol 2010;125:285-294.
12. O'Byrne PM. How much is too much? The treatment of mild asthma. Eur Respir J 2007;30:403-406.
13. Kemeny ME, Rosenwasser LJ, Panettieri RA, Rose RM, Berg-Smith SM, Kline JN. Placebo response in asthma: A robust and objective phenomenon. J Allergy Clin Immunol 2007;119: 1375-1381.
14. Joyce DP, Jackevicius C, Chapman KR, McIvor RA, Kesten S. The placebo effect in asthma drug therapy trials: A meta-analysis. J Asthma 2000;37:303-318.
15. Ahrens RC, Teresi ME, Han S-H, Donnell D, Vanden Burgt JA, Lux CR. Asthma stability after oral prednisone. A clinical model for comparing inhaled steroid potency. Am J Respir Crit Care Med 2001;164:1138-1145.
16. Kelly HW. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin North Am 1999;5: 537-553.
17. Yawn BP. Factors accounting for asthma variability: Achieving optimal symptom control for individual patients. PCRJ 2008;17: 138-147.